Rheumatoid arthritis – an independent risk factor for cardiovascular disease

Česká verzia

Authors: V. Ráček; P. Němec
Authors place of work: Revmatologická ambulance II. interní kliniky Lékařské fakulty MU a FN u sv. Anny Brno, přednosta prof. MUDr. Miroslav Souček, CSc.
Published in the journal: Vnitř Lék 2012; 58(11): 834-838
Category: Reviews

Summary

Mortality in patients with rheumatoid arthritis compared with general population is increased and approximately one-half of the premature death is due to increased cardiovascular mortality. Traditional cardiovascular risk factors only partly explain increased risk of cardiovascular disease in patients with rheumatoid arthritis. The risk of cardiovascular disease associated with rheumatoid arthritis equals that of diabetes mellitus. Rheumatoid arthritis should be regarded as a strong independent cardiovascular risk factor as diabetes mellitus. The presence of chronic inflammation implicated in pathogenesis of rheumatoid arthritis and atherosclerosis could be the key mechanism that contributes to increased cardiovascular risk. Traditional cardiovascular risk factors reduction combined with tight disease control is recommended to reduce the risk of cardiovascular disease.

Key words:
rheumatoid arthritis – cardiovascular disease – mortality

Zdroje

1. Hochberg MC. Adult and juvenile rheumatoid arthritis: current epidemiological concepts. Epidemiol Ref 1981; 3: 27–44.

2. Watson DJ, Rhodes T, Guess HA. All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database. J Rheumatol 2003; 30: 1196–1202.

3. Kvalvik AG, Jones MA, Symmons DP. Mortality in a cohort of Norwegian patients with rheumatoid arthritis followed from 1977 to 1992. Scan J Rheumatol 2000; 29: 29–37.

4. Symmons DP, Jones MA, Scott DL et al. Long-term mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well. J Rheumatol 1998; 25: 1072–1077.

5. Harris ED jr. Rheumatoid arthritis: pathophysiology and implication for therapy. N Engl J Med 1990; 322: 1277–1289.

6. Prior P, Symmons DP, Scott DL. Cause of death in rheumatoid arthritis. Br J Rheumatol 1984; 23: 92–99.

7. Solomon DH, Goodson NJ, Katz JN et al. Patterns of cardiovascular risk in rheumatoid arthritis. Ann Rheum Dis 2006; 65: 1608–1612.

8. Aviña-Zubieta JA, Choi HK, Sadatsafavi M et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008; 59: 1690–1697.

9. Gabriel SE, Crowson CS, Kremmers HM et al. Survival in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005; 52: 722–732.

10. Wallberg-Jonsson S, Ohman ML, Dahlqvist SR. Cardiovascular morbidity and mortality in patients with seropositive arthritis in Northern Sweden. J Rheumatol 1997; 24: 445–451.

11. Solomon DH, Karlson EW, Rimm EB et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003; 107: 1303–1307.

12. Maredit-Kremers H, Crowson CS, Nicola PJ et al. Increased unrecognized coronary heart disease and sudden death in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2005; 52: 402–411.

13. Goodson N, Marks J, Lunt M et al. Cardiovascular admissions and mortality in an inception kohort of patients with rheumatoid arthritis with onset in the 1980s and 1990s. Ann Rheum Dis 2005; 64: 1595–1601.

14. van Halm VP, Peters MJ, Voskuyl AE et al. Rheumatoid arthritis versus type 2 diabetes as a risk factor for cardiovascular disease: a cross-sectional study. Ann Rheum Dis 2009; 68: 1395–1400.

15. Lindhardsen J, Ahlehoff O, Gislason GH et al. The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study. Ann Rheum Dis 2011; 70: 929–934.

16. Kremers HM, Crowson CS, Therneau TM. High ten-year risk of cardiovascular disease in newly diagnosed rheumatoid arthritis patients: a population-based cohort study. Arthritis Rheum 2008; 58: 2268–2274.

17. Cohn JN, Quyyumi AA, Hollenberg NK et al. Surrogate markers for cardiovascular disease: functional markers. Circulation 2004; 109: 31–46.

18. Mancini GB, Dahlöf B, Díez J. Surrogate markers for cardiovascular disease: structural markers. Circulation 2004; 109: 22–30.

19. Ter Avest E, Stalenhoef AF, de Graaf J. What is role of non-invasive measurements of atherosclerosis in individual cardiovascular risk prediction? Clin Sci (Lond) 2007; 112: 507–516.

20. Honda O, Surgiyama S, Kugiyama K et al. Echolucent carotid plaque predict future coronary events in patients with coronary artery disease. J Am Coll Cardiol 2004; 43: 1177–1184.

21. Stamatelopoulos KS, Kotas GD, Papamichael CM et al. Atherosclerosis in rheumatoid arthritis versus diabetes: a comparative study. Arterioscler Thromb Vasc Biol 2009; 29: 1702–1708.

22. Del Rincón ID, Williams K, Stern MP et al. High incidence of cardiovascular events in arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001; 44: 2737–2745.

23. Dessein PH, Joffe BI, Veller MG et al. Traditional and nontraditional cardiovascular risk factors are associated with atherosclerosis in rheumatoid arthritis. J Rheumatol 2005; 32: 435–442.

24. Souverein PC, Berard A, Van Staa TP et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart 2004; 90: 859–865.

25. Del Rincon I, Williams K, Stern MP, Freeman GL, O‘Leary DH, Escalante A: Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. Arthritis Rheum 2003, 48: 1833-1840.

26. Snow MH, Mikuls TR. Rheumatoid arthritis and cardiovascular disease: the role of systemic inflammation and strategies of prevention. Curr Opin Rheumatol 2005; 17: 234–241.

27. Sattar N, McCarey DW, Capell H. Explaining how high-grade systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003; 108: 2957-2963.

28. Libby P. Role of inflammation in atherosclerosis associated with rheumatoid arthritis. Am J Med 2008; 121: 21–31.

29. Bisoendial RJ, Stroes ES, Tak PP. Where the immune response meets the vessel wall. Neth J Med 2009; 67: 328–333.

30. Weyand CM, Gornzy JJ, Luizzo G et al.. T-cell immunity in acute coronary syndromes. Mayo Clin Proc 2001; 76: 1011–1020.

31. Liuzzo G, Goronty JJ, Yang H et al. Monoclonal T-cell proliferation and instability in acute coronary syndromes. Circulation 2000; 101: 2883–2888.

32. Folsom AR, Aleksic N, Cattellier D et al. C-reactive protein and incident coronary heart disease in the Atherosclerosis Risk In Communities (ARIC) study. Am Heart J 2002; 144: 233–238.

33. Wållberg-Jonsson S, Johansson H, Ohman ML et al. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. J Rheumatol 1999; 26: 2562–2571.

34. Goodson NJ, Symmons DP, Scott DG et al. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year follow up study of a primary care-based inception cohort. Arthritis Rheum 2005; 52: 2293–2299.

35. O’Leary DH, Polak JF, Kronmal RA et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med 1999; 340: 14–22.

36. van Sijl AM, Peters MJ, Knol DK et al. Carotid intima media thickness in rheumatoid arthritis as compared to control subject: meta-analysis. Semin Arthritis Rheum 2011; 40: 389–397.

37. Bots ML, Hoes AW, Koudstaal PJ et al. Common carotid intima-media thickness and risk of stroke and myocardial infarction: Rotterdam Study. Circulation 1997; 96: 1432–1437.

38. Panoulas VF, Douglas KM, Milionis HJ et al. Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis. Rheumatology (Oxford) 2007; 46: 1477–1482.

39. Solomon DH, Curhan GC, Rimm EB et al. Cardiovascular risk factors in women with and without rheumatoid arthritis. Arthritis Rheum 2004; 50: 3444–3449.

40. Gonzalez A, Maradit Kremers H, Crowson CS et al. Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients? Ann Rheum Dis 2008; 67: 64–69.

41. Goodson NJ, Silman AJ, Pattison DJ et al. Traditional cardiovascular risk factors measured prior to the onset of inflammatory polyarthritis. Rheumatology (Oxford) 2004; 43: 731–736.

42. Del Rincon I, Williams K, Stern MP, Freeman GL, Escalante A: High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001, 44: 2737-2745.

43. Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med 1999; 340: 115–126.

44. Maradit-Kremers H, Nicola PJ, Crowson CS et al. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005; 52: 722–732.

45. Jacobsson LT, Turesson C, Gülfe A et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005; 32: 1213–1218.

46. van Halm VP, Nurmohamed MT, Twisk JW et al. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther 2006; 8: R151.

47. Carmona L, Descalzo MA, Perez-Pampin E et al. All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumor necrosis factor antagonists. Ann Rheum Dis 2007; 66: 880–885.

48. Haagsma CJ, Blom HJ, van Riel PL et al. Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis. Ann Rheum Dis 1999; 58: 79–84.

49. Clarke R, Daly L, Robinson K et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991; 324: 1149–1155.

50. Cífková R, Rosolová H, Češka R. Prevence kardiovaskulárních onemocnění v dospělém věku. Supplementum Cor Vasa 2005; 47: 3–14.

51. Peters MJ, Symmons DP, McCarey D et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010; 69: 325–331.

52. Manninen V, Elo MO, Frick MH et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988; 260: 641–651.

53. Kinosian B, Glick H, Garland G. Cholesterol and coronary heart disease: predicting risks by levels and ratios. Ann Intern Med 1994; 121: 641–647.

54. Flammer AJ, Sudano I, Hermann F et al. Angiotensin-converting enzyme inhibition improves vascular function in rheumatoid arthritis. Circulation 2008; 117: 2262–2269.

55. Dagenais NJ, Jamali F. Protective effects of angiotensin II interruption: evidence for anti-inflammatory actions. Pharmacotherapy 2005; 25: 1213–1229.

56. Crowson CS, Gabriel SE. Towards improving cardiovascular risk management in patients with rheumatoid arthritis: the need for accurate risk assessment. Ann Rheum Dis 2011; 70: 719–721.

57. Gonzalez-Juanatey C, Llorca J, Testa A et al. Increased prevalence of severe subclinical atherosclerotic findings in long-term treated rheumatoid arthritis patients without clinically evident atherosclerotic disease. Medicine (Baltimore) 2003; 82: 407–413.

58. Franklin J, Farragher TM, Lunt M et al. Excess risk of hospital admission for cardiovascular disease within the first 7 years from onset of inflammatory polyarthritis. Ann Rheum Dis 2010; 69: 1660–1664.

59. Holmqvist ME, Wedrén S, Jacobsson LT et al. Rapid increase in myocardial infarction risk following diagnosis of rheumatoid arthritis amongst patients diagnosed between 1995 and 2006. J Intern Med 2010; 268: 578–585.